Reverse payment patent settlements between brand-name and generic drug manufacturers are subject to antitrust scrutiny under the rule of reason.
competition
Full Federal Court considered the test for substantially lessening competition under s.50 CCA in the context of a rail freight acquisition.
HCA upheld record cartel penalties for wire harness market conduct, affirming that penalties must deter contravener and others, considering nature, extent, and duration of cartel.
Full Federal Court considered whether Pfizer's patent evergreening strategy in the pharmaceutical market constituted misuse of market power under s 46 of the Competition and Consumer Act.
Get a detailed analysis of Federal Trade Commission v Actavis Inc and how it applies to your situation.
Explain Federal Trade Commission v Act...